Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy

Colorectal Disease

Volumn 16, Issue 12, 2014, Pages O420-O430

  Zezos, P ^a,b   Patsiaoura, K ^c   Nakos, A ^a   Mpoumponaris, A ^a   Vassiliadis, T ^a   Giouleme, O ^a   Pitiakoudis, M ^b   Kouklakis, G ^b   Evgenidis, N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

Colonic histology; Eosinophils; Inflammatory bowel disease; Predictive value; Ulcerative colitis; Ulcerative colitis treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; MESALAZINE; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ABSCESS; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLONOSCOPY; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY ASSESSMENT; EOSINOPHILIC INFILTRATION; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INTESTINE CRYPT; LABORATORY TEST; LAMINA PROPRIA; MALE; MUCOSAL EROSION; MUCOSAL ULCERATION; PARAMETERS; REMISSION; STOMACH MUCOSA INJURY; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; BIOPSY; COLITIS, ULCERATIVE; COLON; COMPLICATION; EOSINOPHILIA; INTESTINE MUCOSA; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; BIOPSY; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; EOSINOPHILIA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; MALE; MESALAMINE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84911925198     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12725     Document Type: Article

References (59)

1. Cantor M, Bernstein ChN. Clinical course and natural history of ulcerative colitis. In: Kirsner's Inflammatory Bowel Disease (eds Sartor RB, Sandborn WJ). Toronto: Elsevier, 2004. pp. 280-8.
2. Geboes K, Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut 2002; 50 (Suppl 3): S37-42.
3. Friedman S. General principles of medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 2004; 33: 191-208.
4. Sachar DB. Management of acute, severe ulcerative colitis. J Dig Dis 2012; 13: 65-8.
5. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
6. Triantafillidis JK, Emmanouilidis A, Manousos O et al. Ulcerative colitis in Greece: clinicoepidemiological data, course, and prognostic factors in 413 consecutive patients. J Clin Gastroenterol 1998; 27: 204-10.
7. Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
8. Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-5.
9. Hearing SD, Norman M, Probert CSJ, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999; 45: 382-8.
10. Shinozaki M, Suzuki K, Sawada T, Tsuno N, Higuchi Y, Muto T. Steroid complications and surgery in intractable ulcerative colitis. J Gastroenterol 1998; 33: 196-200.
11. Facklis K, Plevy SE, Vasiliauskas EA et al. Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications. Dis Colon Rectum 1999; 42: 601-6.
12. Shimada T, Hiwatashi N, Yamazaki H, Kinouchi Y, Toyota T. Relationship between glucocorticoid receptor and response to glucocorticoid therapy in ulcerative colitis. Dis Colon Rectum 1997; 40(Suppl 10): S54-8.
13. Markowitz J, Kahn E, Grancher K, Hyams J, Treem W, Daum F. Atypical rectosigmoid histology in children with newly diagnosed ulcerative colitis. Am J Gastroenterol 1993; 88: 2034-7.
14. Tanaka M, Kusumi T, Oshitani N et al. Validity of simple mucosal biopsy criteria combined with endoscopy predicting patients with ulcerative colitis ultimately requiring surgery: a multicenter study. Scand J Gastroenterol 2003; 38: 594-8.
15. Tanaka M, Saito H, Kusumi T et al. Biopsy pathology predicts patients with ulcerative colitis subsequently requiring surgery. Scand J Gastroenterol 2002; 37: 200-5.
16. Desreumaux P, Nutten S, Colombel JF. Activated eosinophils in inflammatory bowel disease: do they matter? Am J Gastroenterol 1999; 94: 3396-8.
17. Yang GY, West AB. What do eosinophils tell us in biopsies of patients with inflammatory bowel disease? J Clin Gastroenterol 2003; 36: 93-8.
18. Al-Haddad S, Riddell RH. The role of eosinophils in inflammatory bowel disease. Gut 2005; 54: 1674-5.
19. Walmsley RS, Ayres RCS, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43: 29-32.
20. Vrij AA, Jansen JM, Schoon EJ, de Bruine A, Hemker HC, Stockbrugger RW. Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. Scand J Gastroenterol Suppl 2001; 234: 41-7.
21. Rothenberg ME. Eosinophilia. N Engl J Med 1998; 338: 1592-600.
22. Simon D, Wardlaw A, Rothenberg ME. Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol 2010; 126: 3-13.
23. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 2004; 113: 11-28.
24. Bischoff SC, Wedemeyer J, Herrmann A et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996; 28: 1-13.
25. Kato M, Kephart GM, Talley NJ et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 1998; 252: 418-25.
26. Rothenberg ME. Gastrointestinal eosinophils. Allergy 2001; 56(Suppl 67): 21-2.
27. Willoughby CP, Piris J, Truelove SC. Tissue eosinophils in ulcerative colitis. Scand J Gastroenterol 1979; 14: 395-9.
28. Sarin SK, Malhotra V, Sen Gupta S, Karol A, Gaur SK, Anand BS. Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis. A prospective controlled study. Dig Dis Sci 1987; 32: 363-7.
29. Dubucquoi S, Janin A, Klein O et al. Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. Gut 1995; 37: 242-6.
30. Makiyama K, Kanzaki S, Yamasaki K, Zea-Iriarte W, Tsuji Y. Activation of eosinophils in the pathophysiology of ulcerative colitis. J Gastroenterol 1995; 30(Suppl 8): 64-9.
31. Raab Y, Fredens K, Gerdin B, Hallgren R. Eosinophil activation in ulcerative colitis: studies on mucosal release and localization of eosinophil granule constituents. Dig Dis Sci 1998; 43: 1061-70.
32. Bischoff SC, Mayer J, Nguyen QT, Stolte M, Manns MP. Immunohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3521-9.
33. Jeziorska M, Haboubi N, Schofield P, Woolley DE. Distribution and activation of eosinophils in inflammatory bowel disease using an improved immunohistochemical technique. J Pathol 2001; 194: 484-92.
34. Carvalho AT, Elia CC, de Souza H et al. Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J Clin Gastroenterol 2003; 36: 120-5.
35. Kristjansson G, Venge P, Wanders A, Loof L, Hallgren R. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut 2004; 53: 1806-12.
36. Lampinen M, Rönnblom A, Amin K et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 2005; 54: 1714-20.
37. Bischoff SC, Grabowsky J, Manns MP. Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci 1997; 42: 394-403.
38. Saitoh O, Kojima K, Sugi K et al. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3513-20.
39. Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol 2002; 97: 1755-62.
40. Carlson M, Raab Y, Peterson C, Hallgren R, Venge P. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol 1999; 94: 1876-83.
41. Sangfelt P, Carlson M, Thorn M, Loof L, Raab Y. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am J Gastroenterol 2001; 96: 1085-90.
42. Levy AM, Gleich GJ, Sandborn WJ, Tremaine WJ, Steiner BL, Phillips SF. Increased eosinophil granule proteins in gut lavage fluid from patients with inflammatory bowel disease. Mayo Clin Proc 1997; 72: 117-23.
43. Lamas AM, Leon OG, Schleimer RP. Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. J Immunol 1991; 147: 254-9.
44. Lampinen M, Carlson M, Sangfelt P et al. IL-5 and TNF-alpha participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Dig Dis Sci 2001; 46: 2004-9.
45. Zagai U, Skold CM, Trulson A, Venge P, Lundahl J. The effect of eosinophils on collagen gel contraction and implications for tissue remodeling. Clin Exp Immunol 2004; 135: 427-33.
46. Phipps S, Ying S, Wangoo A, Ong YE, Levi-Schaffer F, Kay AB. The relationship between allergen-induced tissue eosinophilia and markers of repair and remodeling in human atopic skin. J Immunol 2002; 169: 4604-12.
47. Binder V, Elsborg L, Greibe J et al. Disodium cromoglycate in the treatment of ulcerative colitis and Crohn's disease. Gut 1981; 22: 55-60.
48. Heatley RV, James PD. Eosinophils in the rectal mucosa. A simple method of predicting the outcome of ulcerative proctocolitis? Gut 1979; 20: 787-91.
49. Benfield GF, Asquith P. Blood eosinophilia and ulcerative colitis-influence of ethnic origin. Postgrad Med J 1986; 62: 1101-5.
50. Benfield GF, Bryan R, Crocker J. Lamina propria eosinophils and mast cells in ulcerative colitis: comparison between Asians and Caucasians. J Clin Pathol 1990; 43: 27-31.
51. D'Arienzo A, Manguso F, Astarita C et al. Allergy and mucosal eosinophil infiltrate in ulcerative colitis. Scand J Gastroenterol 2000; 35: 624-31.
52. Moum B, Aadland E, Ekbom A, Vatn MH. Seasonal variations in the onset of ulcerative colitis. Gut 1996; 38: 376-8.
53. Aratari A, Papi C, Galletti B et al. Seasonal variations in onset of symptoms in Crohn's disease. Dig Liver Dis 2006; 38: 319-23.
54. Karamanolis DG, Delis KC, Papatheodoridis GV, Kalafatis E, Paspatis G, Xourgias VC. Seasonal variation in exacerbations of ulcerative colitis. Hepatogastroenterology 1997; 44: 1334-8.
55. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
56. Bitton A, Peppercorn MA, Antonioli DA et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20.
57. Hogan SP, Rothenberg ME. Review article: the eosinophil as a therapeutic target in gastrointestinal disease. Aliment Pharmacol Ther 2004; 20: 1231-40.
58. Wedemeyer J, Vosskuhl K. Role of gastrointestinal eosinophils in inflammatory bowel disease and intestinal tumours. Best Pract Res Clin Gastroenterol 2008; 22: 537-49.
59. Hogan SP, Waddell A, Fulkerson PC. Eosinophils in infection and intestinal immunity. Curr Opin Gastroenterol 2013; 29: 7-14.